PerkinElmer recently launched an online, open-access COVID-19 data dashboard for the global scientific community.
The dashboards are powered by the company’s data analytics and data visualization solutions to help researchers quickly and easily leverage large amounts of drug compounds and clinical trial data.
The COVID-19 dashboards are supported by PerkinsElmer’s Signals Lead Discovery and the TIBCO Spotfire advanced analytics platform with built-in artificial intelligence functionality. They offer an easy to use solution for searching, aggregating and visualizing complex, scientific data.
Using the platform, scientists can narrow down the 1.6 million compounds that are publicly available by querying a curated chemical substance dataset and related activity data provided by a division of the American Chemical Society known as CAS.
CAS COVID-19 Antiviral Candidate Compound data is an open source Data collection Assembled by scientists in the CAS registry. It has more than 50,000 known antiviral drugs and related chemical compounds that are structurally similar to known antivirals. The database combined with the dashboard’s ability to cross-reference against 15 million bioactivity data points of drug-like molecules can help researchers narrow the field down to 100 or fewer key compounds.
The other resource offered by the company is the COVID-19 Clinical Trial Dashboard. That dashboard pulls together data from sources where scientists can select the relevant information on trials including trial status, lead organizations, drug compounds being studied, antibody, antiviral or DNA-based vaccine approaches.
“As global scientists work tirelessly to create or repurpose antiviral drugs and vaccines for COVID-19, there are massive amounts of existing public data that can be invaluable to these efforts. However, bringing together, combing through and harnessing that data in real-time can be a real challenge,” VP and GM of informatics Kevin Willoe said in a news release. “By collaborating with organizations like TIBCO and CAS on the new PerkinElmer COVID-19 Dashboards, we put the power of analytics at the fingertips of scientists to help drive actionable insights earlier in the discovery process. These dashboards are tools to help them spend more time being scientists and less time being data managers — which is critical when working to combat the challenges faced by COVID-19 researchers.”
PerkinElmer suggests the two platforms could help scientists around the world fight the COVID-19 pandemic. The company also said it is committed to donating instruments and testing kits around the world to help screen and diagnose the disease and hotspot location.
Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development, Infectious Disease
